September 1 (SeeNews) - Bulgarian drug trader Sopharma Trading [BUL:SFT] reported a consolidated net profit of 15.8 million levs ($8.07 million/8.08 million euro) in the first half of 2022, up from 6.19 million levs in the same period of 2021.
The company’s total revenue rose to 722.8 million levs in the first six months levs from 647.6 million levs in the comparable period of last year, Sopharma Trading said in an interim financial statement earlier this week.
Operating expenses increased to 701.9 million levs from 637.3 million levs, mostly because of higher cost of goods sold.
Sopharma Trading booked a solid performance in the second quarter of 2022, with sales of 353.7 million levs. Sales of products in the company's pharmacy network accounted for 60.05% of total sales, while sales to hospitals formed 23.37%.
The company controlled a share of 22.3% of the Bulgarian pharmaceuticals market in the second quarter. It had a market share of 19.37% in the pharmacy segment, while in the hospital segment its share stood at 30.56%.
Sopharma Trading is a unit of Bulgarian pharmaceuticals producer Sopharma [BUL:SFA], which held a stake 83.24% in the company at the end of June.
By 1509 CEST on Thursday, Sopharma Trading's shares traded 3.92% higher at 5.30 levs on the Sofia bourse.
(1 euro = 1.95583 levs)